- Home
- FATE vs PLX Comparison
FATE vs PLX Comparison
Compare FATE & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- PLX
- Stock Information
- Founded
- FATE 2007
- PLX 1993
- Country
- FATE United States
- PLX Israel
- Employees
- FATE N/A
- PLX N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FATE Health Care
- PLX Health Care
- Exchange
- FATE Nasdaq
- PLX Nasdaq
- Market Cap
- FATE 142.4M
- PLX 160.2M
- IPO Year
- FATE 2013
- PLX 1998
- Fundamental
- Price
- FATE $1.42
- PLX $2.39
- Analyst Decision
- FATE Hold
- PLX Strong Buy
- Analyst Count
- FATE 10
- PLX 1
- Target Price
- FATE $6.75
- PLX $15.00
- AVG Volume (30 Days)
- FATE 2.1M
- PLX 646.5K
- Earning Date
- FATE 03-04-2025
- PLX 03-13-2025
- Dividend Yield
- FATE N/A
- PLX N/A
- EPS Growth
- FATE N/A
- PLX N/A
- EPS
- FATE N/A
- PLX N/A
- Revenue
- FATE $13,447,000.00
- PLX $45,667,000.00
- Revenue This Year
- FATE N/A
- PLX N/A
- Revenue Next Year
- FATE N/A
- PLX $63.84
- P/E Ratio
- FATE N/A
- PLX N/A
- Revenue Growth
- FATE N/A
- PLX N/A
- 52 Week Low
- FATE $1.04
- PLX $0.82
- 52 Week High
- FATE $8.83
- PLX $2.76
- Technical
- Relative Strength Index (RSI)
- FATE 48.76
- PLX 48.43
- Support Level
- FATE $1.43
- PLX $2.43
- Resistance Level
- FATE $1.81
- PLX $2.73
- Average True Range (ATR)
- FATE 0.14
- PLX 0.13
- MACD
- FATE 0.05
- PLX -0.04
- Stochastic Oscillator
- FATE 39.06
- PLX 13.95
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.